Clinical trials: Hematological Patients
Acute Myeloid Leukemias, Advanced Hematological Malignancies
Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells
Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation.
- Conditions
- Acute Myeloid Leukemias, Advanced Hematological Malignancies, Indication for Allogeneic Stem Cell Transplantation, no HLA-identical Donor Available
- Trial name
- NCT01220544
- Testing
- Haploidentical transplantation with donor NK cells
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Hematopoietic and Lymphatic System Neoplasm
Sustained Oral Fiber Supplementation for Patients Undergoing Treatment for Hematological Malignancies
This clinical trial examines sustained oral fiber supplementation for patients undergoing treatment for hematological malignancies.
- Trial name
- NCT04829136
- Testing
- Kate Farms 1.0, Standard of Care Nutritional Support, Survey Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
A Study in Leukemia Patients With Karonudib
The primary objective of this study is to determine safety and tolerability of Karonudib for the treatment of hematological malignancies.
- Trial name
- MAATEO (NCT04077307)
- Testing
- Karonudib
- Where
- 7 sites in Denmark, Serbia and 1 more
- Volunteers
- 50 people
- Sponsor
- Thomas Helleday Foundation
Hematological Abnormalities in covid19
Hematological Disorders in Covid 19 Patients
aim of the research is to detect hematological abnormalities in covid 19 patients and its correlation with the severity and outcome of the disease.
- Trial name
- NCT05182528
- Volunteers
- 200 people
- Sponsor
- Assiut University
Septic Shock, Anemia
TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock
Septic shock is a frequent complication associated with high mortality in patients with malignancies. The best transfusion strategy (restrictive or liberal) for the resuscitation of septic shock remains a controversial issue, in…
- Conditions
- Septic Shock, Anemia, Cancer
- Trial name
- TRANSPORT (NCT03837171)
- Testing
- Liberal Red blood cell transfusion, Restrictive Red blood cell transfusion
- Where
- 20 sites in France
- Volunteers
- 192 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
This phase I trial studies the side effects and the best dose of everolimus when given together with bendamustine hydrochloride in treating patients with cancer of the blood (hematologic cancer) that has returned after a period…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02240719
- Testing
- everolimus, bendamustine hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Davis
Hematopoietic Malignancy, Relapse/Recurrence
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
About 33% of patients with myeloid or lymphoid malignancies experience relapse with HLA loss after haplo-HSCT. Due to the specificity of HLA-loss relapse, the 2019 European Society for Blood and Marrow Transplantation (EBMT)…
- Conditions
- Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06125483
- Testing
- Umbilical Cord Blood Transplantation
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Paroxysmal Nocturnal Hemoglobinuria
Hematological Response in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5 Antibody: an External Control Arm Study for Iptacopan Use in Anti-C5 naïve Patients
The aim of this non-interventional secondary use of data study is to evaluate hematological response in patients with paroxysmal nocturnal hemoglobinuria and anemia in the 6-month period after initiation of anti-C5 antibody…
- Trial name
- APPEX (NCT05842486)
- Testing
- Anti-C5 antibody treatment
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Fungal Infections
Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies
The primary objective of this study is to evaluate invasive fungal infections (IFI) according to clinicians' opinion vs the opinion of an independent board of experts.
- Trial name
- NCT04024995
- Where
- 14 sites in Italy
- Volunteers
- 513 people
- Sponsor
- Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne
Pancreatic Cancer
Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma Patients
By evaluating the nutritional status of patients with pancreatic ductal adenocarcinoma (PDAC) admitted to Jinling Hospital, collecting relevant clinical data.
- Trial name
- NCT06378853
- Testing
- no intervention
- Where
- China
- Volunteers
- 548 people
- Sponsor
- Jinling Hospital, China
Invasive Aspergillosis in Patients With Onco-haematological Diseases
Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis
The purpose of this study is to evaluate the performances of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
- Trial name
- MYCOGENIE (NCT03349931)
- Testing
- DNA extraction and detection of Aspergillus fumigatus in serum samples
- Where
- 6 sites in France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Leukemias, Aplastic Anemia
Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells in combination with a toxicity reduced conditioning regimen or with standard conditioning regimens according to underlying disease.
- Conditions
- Acute Leukemias, Aplastic Anemia, Childhood Solid Tumor
- Trial name
- NCT01919866
- Testing
- Transplantation of CD3/CD19 depleted stem cells
- Where
- 5 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- University Children's Hospital Tuebingen
Hematologic Malignancy
Oral Complications in Hematological Malignancies
The aim of this study was to evaluate the prevalence and types of oral complications found in patients diagnosed with haematological malignancy
- Trial name
- NCT05758207
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Vascular Access Complication
Vascular Access in Hematological Patients - PICC Versus CVC
The use of peripherally inserted central catheters (PICCs) represents a major advance for hematological patients, enabling the effective delivery of chemotherapy and/or blood products particularly for prolonged infusions or in…
- Trial name
- NCT02405728
- Testing
- Centrally inserted central catheters (CICCs), Peripherally inserted central catheters (PICCs)
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Federico II University
High-risk Leukemias
"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"
Phase I / II study on infusion of alloreactive or stimulated Natural Killer cells with IL-15 ex vivo after haploidentical transplantation of hematopoietic progenitors in pediatric patients with hematologic malignancies (PHINK
- Trial name
- PHINK (NCT05304754)
- Testing
- NK cells stimulated ex vivo with IL-15, Alloreactive NK cells
- Where
- 10 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Polycythemia Vera, Essential Thrombocythemia
A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic…
- Trial name
- NCT00866762
- Testing
- HDAC inhibitor (MK-0683)
- Where
- 16 sites in Denmark, Netherlands and 2 more
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital at Herlev
Hematological Malignancies
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.
- Trial name
- NCT05454241
- Testing
- Anti-CD7 CAR-T
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematological Malignancies
Study of AZD9829 in CD123+ Hematological Malignancies
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
- Trial name
- NCT06179511
- Testing
- AZD9829
- Where
- 22 sites in United States, Australia and 8 more
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Hematological Malignancies
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
- Trial name
- NCT04260698
- Testing
- omidubicel
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gamida Cell ltd
Tumor Lysis Syndrome
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect…
- Trial name
- FLORET (NCT03605212)
- Testing
- Febuxostat
- Where
- 17 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 30 people
- Sponsor
- Menarini Group